The Danish pharmaceutical company behind obesity drug Wegovy, Novo Nordisk, plans to invest US$1.09bn in expanding its facility in Minas Gerais, southeast Brazil. The 74,000-sq-m project will be used for…

Novo Nordisk, the Danish company that makes diabetes drug Ozempic and obesity treatment Wegovy, has begun work on a 5.3ha quality control centre in Hillerød, about 20km north of Copenhagen.…

French drugmaker Sanofi has confirmed its plan to spend €1.3bn on an insulin factory at its site near Frankfurt, website BioProcess International reports. The 36,000-sq-m plant will replace a previous…

Danish drugmaker Novo Nordisk, the firm behind the highly sought-after diabetes treatment Ozempic and obesity treatment Wegovy, will spend $4.1bn on a new factory in North Carolina. The 1.4 million-sq-ft…